1. Molecular properties of monoamine oxidases A and B

   • Sau-Wah Kwan
   • J. M. Bergeron
   • C. W. Abell

   Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S1 - S5

2. Biochemistry and pharmacology of moclobemide, a prototype RIMA

   • W. Haefely
   • W. P. Burkard
   • M. Da Prada

   Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S6 - S14

3. Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide

   • A. M. Cesura
   • R. Kettler
   • M. Da Prada

   Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S15 - S16

4. Brain microdialysis in rats: a technique to reveal competition in vivo between endogenous dopamine and moclobemide, a RIMA antidepressant

   • A. Colzi
   • F. d'Agostini
   • M. Da Prada

   Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S17 - S20

5. Molecular neuroanatomy of monoamine oxidases in human brainstem

   • J. G. Richards
   • J. Saura
   • M. Da Prada

   Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S21 - S23

6. Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies

   • R. Amrein
   • T. W. Güntert
   • W. Schmid-Burgk

   Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S24 - S31

7. Tyramine content of preserved and fermented foods or condiments of Far Eastern cuisine

   • M. Da Prada
   • G. Zürcher

   Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S32 - S34

8. Interaction of moclobemide and tricyclic antidepressants with the tyramine pressor effect in rats

   • W. Burkard
   • F. d'Agostini
   • M. Da Prada

   Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S35 - S36

9. Pharmacokinetic and metabolic aspects of the moclobemide-food interaction

   • A. F. D. Cole
   • J. G. Baxter
   • D. Lalka

   Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S37 - S39

10. Influence of moclobemide on ibuprofen-induced faecal blood loss

    • T. W. Güntert
    • M. Schmitt
    • J. H. G. Jonkman

    Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S40 - S42

11. MAOIs to RIMAs in anaesthesia — a literature review

    • S. Hill
    • K. Yau
    • J. Whitwam

    Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S43 - S45

12. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations

    • J. Dingemanse
    • A. Korn
    • T. W. Güntert

    Section I RIMA: Pharmacology, Biochemistry And Interactions Pages: S46 - S48

13. Behavioural toxicity of antidepressants with particular reference to moclobemide

    • I. Hindmarch
    • J. Kerr

    Section II Psychomotor Performance And Cognitive Performance Pages: S49 - S55

14. Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline

    • H. Allain
    • A. Lieury
    • J. M. Gandon

    Section II Psychomotor Performance And Cognitive Performance Pages: S56 - S61

15. Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo

    • J. G. Ramaekers
    • H. F. Swijgman
    • J. F. O'Hanlon

    Section II Psychomotor Performance And Cognitive Performance Pages: S62 - S67

16. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects

    • J. Dingemanse
    • I. Berlin
    • A. J. Puech

    Section II Psychomotor Performance And Cognitive Performance Pages: S68 - S70

17. Epidemiology of depression

    • J. Angst

    Section III Current Issues In Depression Pages: S71 - S74

18. Differentiation between major and minor depression

    • M. Philipp
    • C. D. Delmo
    • O. Benkert

    Section III Current Issues In Depression Pages: S75 - S78

19. Depression in the community: a comparison of treated and non-treated cases in two non-referred samples

    • W. Maier
    • D. Lichtermann
    • M. Fickinger

    Section III Current Issues In Depression Pages: S79 - S81

20. Relationship of anxiety and depression

    • A. Frances
    • D. Manning
    • M. Kline

    Section III Current Issues In Depression Pages: S82 - S86

21. Methodology of measuring the efficacy of antidepressants

    • F. M. Quitkin

    Section III Current Issues In Depression Pages: S87 - S89

22. Methodology of measuring the efficacy of antidepressants — European viewpoint

    • B. Woggon

    Section III Current Issues In Depression Pages: S90 - S92

23. Active control equivalence trials: some methodological aspects

    • U. Ferner
    • N. Neumann

    Section III Current Issues In Depression Pages: S93 - S95

24. Theoretical considerations and perspectives on the onset of action of moclobemide

    • J. -P. Gachoud
    • H. Mikkelsen
    • R. Jouvent

    Section III Current Issues In Depression Pages: S96 - S97

25. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study

    • D. Bakish
    • J. Bradwejn
    • L. Bulger

    Section IV Clinical Efficacy Pages: S98 - S101

26. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III)

    • T. Bougerol
    • C. Uchida
    • H. Mikkelsen

    Section IV Clinical Efficacy Pages: S102 - S108

27. Efficacy of moclobemide in different patient groups: a meta-analysis of studies

    • J. Angst
    • M. Stabl

    Section IV Clinical Efficacy Pages: S109 - S113

28. Moclobemide and placebo in mild major depression: a double-blind randomized trial

    • E. Ose
    • P. Holm

    Section IV Clinical Efficacy Pages: S114 - S115

29. A double-blind comparison of moclobemide and amineptine in the treatment of depressed out-patients

    • J. P. Macher
    • C. Mirabaud

    Section IV Clinical Efficacy Pages: S116 - S117

30. A double-blind comparison of moclobemide and toloxatone in out-patients presenting a major depressive disorder

    • P. Lemoine
    • C. Mirabaud

    Section IV Clinical Efficacy Pages: S118 - S119

31. Long-term treatment with moclobemide. An open-label, non-comparative, multiple-distributed study in patients with a major depressive episode as defined by DSM-III

    • E. Moll
    • M. Stabl
    • R. Amrein

    Section IV Clinical Efficacy Pages: S120 - S122

32. Patients at risk of suicide and overdose

    • G. Beaumont
    • W. Hetzel

    Section V Special Patient Groups Pages: S123 - S126

33. Safety of moclobemide taken in overdose for attempted suicide

    • W. Hetzel

    Section V Special Patient Groups Pages: S127 - S129

34. Post-stroke depression

    • J. W. G. Tiller

    Section V Special Patient Groups Pages: S130 - S133

35. Use of moclobemide in children with attention deficit hyperactivity disorder

    • G. E. Trott
    • H. J. Friese
    • G. Nissen

    Section V Special Patient Groups Pages: S134 - S136

36. Depression and senile dementia of the Alzheimer type: a role for moclobemide

    • V. Chan-Palay

    Section V Special Patient Groups Pages: S137 - S139

37. Moclobemide: a range of opportunities

    • R. G. Priest

    Section VI Condusions Pages: S140 - S141